The UK could lose out on £11 billion in pharmaceuticals research and development (R&D) investment by 2033

Every morning, an elderly woman enters a crowded NHS clinic in Manchester, clutching a prescription for a groundbreaking drug that could alleviate her chronic pain. Yet, unbeknownst to her, the future availability of such medicines is hanging by a thread, threatened by financial policies that may push pharmaceutical companies away from investing in the UK. According to a recent report by WPI Economics, the repercussions could be dire: the UK stands to lose £11 billion in pharmaceutical R&D investment by 2033.

The Heart of the Matter: Volatile Pricing Mechanisms

At the crux of this looming crisis are the stringent pricing control mechanisms established under the Voluntary Scheme or VPAG. This scheme now mandates that pharmaceutical companies remit up to 35.6% of their UK revenues from branded medicines to the NHS. The spiraling payment rates have left the UK out of sync with comparable countries, which offer significantly lower rebate rates. For instance, France operates at 5.7%, while Germany and Italy maintain rates of 7% and 6.8%, respectively. As a result, companies are seeking investment opportunities in more favorable environments abroad.

Evidence of Flight

Data reveals a disturbing trend: investment in R&D and manufacturing is increasingly migrating to nations that provide a more conducive climate for pharmaceutical companies. A report by the life sciences consultancy BioStrategies indicates that 66% of pharmaceutical firms are redirecting their investments to the U.S., citing the high UK payment rates as a deterrent.

• The UK is at risk of losing its status as a leading player in health innovation.
• Over the past five years, 20% of the new medicines proposed for the NHS have been terminated, doubling from the previous five years.
• In 2023 alone, over 15 new active substances were not launched within the NHS framework.

The Human Toll

The consequences of this financial squeeze extend beyond numbers and statistics; they resonate in heart-wrenching stories across the UK. Richard Torbett, Chief Executive of the ABPI, stresses: “The burden of high repayment rates on company revenues is an obstacle to growth. If not addressed, we risk generating poorer health outcomes and exacerbating health inequalities.”

Voices from the Industry

Executives from industry giants reflect a collective concern:

Peter Wickersham, Vice President of Gilead Sciences UK, emphasizes, “The excessive and unpredictable VPAG rates are undermining the potential for the UK to be a global leader in life sciences. We must move toward a fairer model that fosters innovation.”

This sentiment resonates deeply with many in the pharmaceutical sector. Kylie Bromley, Vice President at Biogen, notes: “The size and unpredictability of the rebates have overshadowed the positive aspects of the UK’s life sciences ecosystem.”

Potential Paths Forward

WPI Economics suggests that if the new medicine payment rates can revert to pre-2023 levels of below 10%, the UK could not only safeguard R&D investments but also boost its GDP by £61 billion over the next three decades. This projection could generate an additional £20 billion in tax revenue. So what must be done?

A Call to Action

Industry leaders propose a multi-faceted approach:

• Re-evaluate the VPAG system to align UK rates with international standards.
• Streamline the process for new medicine approvals, which have stagnated due to outdated benchmarks.
• Foster collaborations between pharmaceutical companies and NHS to ensure mutual benefit.

Matthew Oakley, Founder of WPI Economics, warns, “Failure to address these issues will not only affect investment but also lead to poorer health outcomes. The time for decisive action is now.”

Looking Ahead

As the elderly woman in Manchester continues her search for relief, the looming specter of high payment rates suggests that her story might become an all-too-common narrative. Research from the International Journal of Healthcare Policy indicates that countries with robust, supportive frameworks for pharmaceuticals not only improve patient outcomes but also create a thriving economy. If the UK wishes to reclaim its rightful position as a leader in life sciences, urgent policy reforms must be prioritized now.

As Johnson & Johnson’s Roz Bekker succinctly puts it, “Immediate government intervention is vital to unlock our country’s potential.” In the delicate balance between public health and economic viability, the UK must not allow itself to slip into a healthcare abyss where innovative solutions remain tantalizingly out of reach.

Source: www.abpi.org.uk